Thornhill, Canada Clinical Trials

A listing of Thornhill, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 120 clinical trials
featured
C2541013 MIRNA NASH  

The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor). This study is specifically designed to evaluate the effect of a range of doses of DGAT2i alone, and DGAT2i + ACCi, on resolution of NASH or improvement …

Toronto Liver Centre
 (9.0 away)
  • 261 views
  • 19 Jul, 2021
  • +64 other locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

bendamustine
rituximab
cyclin d1
acalabrutinib
Research Site
 (7.2 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Sunnybrook Odette Cancer Centre
 (7.2 away) Contact site
  • 2496 views
  • 24 Jul, 2021
  • +209 other locations
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- Early Breast Cancer

Novartis Investigative Site
 (7.2 away) Contact site
  • 211 views
  • 17 Jul, 2021
  • +362 other locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate …

olaparib
ct scan
prostate adenocarcinoma
MRI
adenocarcinoma
Research Site
 (7.2 away) Contact site
  • 200 views
  • 23 Jul, 2021
  • +194 other locations
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Sunnybrook Health Science Centre ( Site 0210)
 (7.2 away) Contact site
  • 135 views
  • 25 Jul, 2021
  • +146 other locations
An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Dimethyl Fumarate or Fingolimod to Ofatumumab

The open label study to evaluate effectiveness of treatment with ofatumumab in patients transitioning from commonly used oral MS therapies - fingolimod or dimethyl fumarate, due to breakthrough disease.

dimethyl fumarate
fingolimod
ofatumumab
Novartis Investigative Site
 (7.2 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +116 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (5.5 away) Contact site
  • 50 views
  • 11 Jul, 2021
  • +223 other locations
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Galderma Investigational Site 8336
 (4.0 away) Contact site
  • 21 views
  • 16 Jul, 2021
  • +470 other locations
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared With Carboplatin-Pemetrexed in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

cancer chemotherapy
measurable disease
carboplatin
pemetrexed
epidermal growth factor
Sunnybrook Health Sciences Centre
 (7.2 away) Contact site
  • 0 views
  • 25 Jul, 2021
  • +274 other locations